Heart rate and blood pressure variability in patients with myasthenia gravis

This cross-sectional case control study included subjects aged between 18 and 65 years with diagnosis of myasthenia gravis (MG) in Osserman's Stage I and Stage IIa and those in remission with positive and negative acetylcholine receptor antibody (AChRAb). They were evaluated for heart rate variability (HRV) and other conventional autonomic functions. Patients with co-morbidities that can affect autonomic nervous system were excluded. Repetitive nerve stimulation test (RNST), nerve conduction test, AChRAb assay, and computerized tomography (CT) of chest were done in all the patients. All patients of MG who fulfilled the inclusion criteria had a minimum drug-free period of 6 h which was followed by HRV and other conventional tests. Thirty subjects fulfilling study criteria and an equal number of age and gender-matched healthy subjects were enrolled as controls. Autonomic function tests revealed significant changes in HRV (both time and frequency domain) parameters suggestive of parasympathetic deficiency as well as shifting of sympathovagal balance towards raised sympathetic tone. With regards to conventional autonomic function tests, there was statistically significant decrease in values of heart rate-based tests as well as blood pressure-based test (isometric handgrip test) in study group compared with controls, again indicative of significant parasympathetic deficiency and minimal sympathetic deficiency. We conclude that in MG, cholinergic transmission is affected more diffusely than previously thought.

[1]  S. Calvano,et al.  RELATIONSHIP OF BASAL HEART RATE VARIABILITY TO IN VIVO CYTOKINE RESPONSES after endotoxin exposure , 2010, Shock.

[2]  Shigeaki Suzuki,et al.  Autoimmune targets of heart and skeletal muscles in myasthenia gravis. , 2009, Archives of neurology.

[3]  R. Barohn,et al.  Myasthenia gravis, thymoma, and intestinal pseudo-obstruction: a case report and review. , 2003, Journal of clinical neuromuscular disease.

[4]  R. Paul,et al.  What have we learned about cognition in myasthenia gravis?: a review of methods and results , 2001, Neuroscience & Biobehavioral Reviews.

[5]  G. Farrugia,et al.  Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. , 2000, The New England journal of medicine.

[6]  R. Longhi,et al.  Antibodies against neuronal nicotinic receptor subtypes in neurological disorders , 2000, Journal of Neuroimmunology.

[7]  M. Messier,et al.  [Paradoxal lowering of parasympathetic indices in myasthenic patients]. , 1999, Archives des maladies du coeur et des vaisseaux.

[8]  S. Kaplan,et al.  Detrusor Areflexia in a Patient with Myasthenia Gravis , 1998, International journal of urology : official journal of the Japanese Urological Association.

[9]  R. Barohn,et al.  Acetylcholine receptor antibodies in the Lambert‐Eaton myasthenic syndrome , 1998, Neurology.

[10]  F. Aitcheson,et al.  Intestinal pseudo-obstruction, myasthenia gravis, and thymoma , 1996, Neurology.

[11]  P. O'Suilleabhain,et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. , 1995, The New England journal of medicine.

[12]  V. Gerzanich,et al.  Neuronal Nicotinic Receptor Subtypes , 1995, Annals of the New York Academy of Sciences.

[13]  K. McEvoy Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. , 1994, Neurologic clinics.

[14]  D. Theobald,et al.  Acute intestinal pseudo-obstruction due to malignant thymoma. , 1993, Singapore medical journal.

[15]  E. Stoica,et al.  Deficiency of sympathetic nervous system function in myasthenia. , 1992, Journal of the autonomic nervous system.

[16]  R. F. Mayer,et al.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome , 1988, Journal of the Neurological Sciences.

[17]  W. Campbell,et al.  Malignant thymoma with dysautonomia and disordered neuromuscular transmission. , 1986, Archives of neurology.

[18]  D. B. Drachman,et al.  Myasthenia gravis. , 1994, The New England journal of medicine.